PDF下载 ( 2092 KB)
局部枸橼酸抗凝在肝衰竭患者连续性肾脏替代治疗中的应用
DOI: 10.3969/j.issn.1001-5256.2021.01.044
作者贡献声明：金源源拟定写作思路，查阅文献资料，撰写文章；诸炳骅、费雪洁指导写作思路，指导撰写文章; 王倩基金支持，修改文章并最后定稿。
Clinical application of regional citrate anticoagulation in continuous renal replacement therapy for patients with liver failure
-
摘要: 体外抗凝是连续性肾脏替代治疗(CRRT)的一项关键技术，肝素曾是CRRT首选的抗凝剂，但由于出血风险高，临床使用受限。枸橼酸作为一种新型局部抗凝剂，近年来受到越来越多的关注和推荐，但对于肝衰竭患者的应用一直存在争议。通过阅读近年来国内外相关文献，就局部枸橼酸抗凝在肝衰竭患者中的代谢特点、监测方法及其在CRRT应用中的安全性进行综述。Abstract: In vitro anticoagulation is a key technique in continuous renal replacement therapy (CRRT), and heparin was once the preferred anticoagulant for CRRT, but its clinical application is limited due to the high risk of bleeding. Citrate, as a new regional anticoagulant, has received more and more attention and recommendation in recent years, but there are still controversies over its application in patients with liver failure. With reference to relevant literature in China and globally, this article reviews the metabolic characteristics and monitoring methods of regional citrate anticoagulation and its safety in CRRT for patients with liver failure.
-
Key words:
- Liver Failure /
- Citrate /
- Renal Replacement Therapy
-
[1] EAST JM, CSERTI-GAZDEWICH CM, GRANTON JT. Heparin-induced thrombocytopenia in the critically ill patient[J]. Ches, 2018, 154(3): 678-690. DOI: 10.1016/j.chest.2017.11.039 [2] KHWAJA A. KDIGO clinical practice guidelines for acute kidney injury[J]. Nephron Clin Pract, 2012, 120(4): c179-c184. http://www.karger.com/Article/Abstract/339789 [3] CHEN XM, DING XQ, WANG Q, et al. Blood purification standard operating procedure (SOP)[M]. 2020 ed. Beijng: The People's Military Medical Association, 2020: 151. (in Chinese)陈香美, 丁小强, 王荣, 等. 血液净化标准操作规程[M]. 2020版.北京:人民军医出社, 2020: 151. [4] HARTMANN J, STROBL K, FICHTINGER U, et al. In vitro investigations of citrate clearance with different dialysis filters[J]. Int J Artif Organs, 2012, 35(5): 352-359. DOI: 10.5301/ijao.5000098 [5] MARIANO F, MORSELLI M, BERGAMO D, et al. Blood and ultrafiltrate dosage of citrate as a useful and routine tool during continuous venovenous haemodiafiltration in septic shock patients[J]. Nephrol Dial Transplant, 2011, 26(12): 3882-3888. DOI: 10.1093/ndt/gfr106 [6] HUANG YL, CHEN YH, YUAN L, et al. Application of local anticoagulation with citrate in hemodialysis of patients with high risk of bleeding tendency[J]. J Clin Exp Med, 2019, 18(18): 2002-2005. (in Chinese) DOI: 10.3969/j.issn.1671-4695.2019.18.029黄艳玲, 陈永华, 袁利, 等. 高危出血倾向患者血液透析中局部枸橼酸抗凝的应用[J]. 临床和实验医学杂志, 2019, 18(18): 2002-2005. DOI: 10.3969/j.issn.1671-4695.2019.18.029 [7] SHUM HP, YAN WW, CHAN TM. Risks and benefits of citrate anticoagulation for continuous renal replacement therapy[J]. Hong Kong Med J, 2015, 21(2): 149-154. http://www.ncbi.nlm.nih.gov/pubmed/25477338 [8] ZHANG W, BAI M, YU Y, et al. Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: A systematic review and meta-analysis[J]. Crit Care, 2019, 23(1): 22. DOI: 10.1186/s13054-019-2317-9 [9] GAO J, WANG F, WANG Y, et al. A mode of CVVH with regional citrate anticoagulation compared to no anticoagulation for acute kidney injury patients at high risk of bleeding[J]. Sci Rep, 2019, 9(1): 6607. DOI: 10.1038/s41598-019-42916-1 [10] LEUNG AK, SHUM HP, CHAN KC, et al. A retrospective review of the use of regional citrate anticoagulation in continuous venovenous hemofiltration for critically ill patients[J]. Crit Care Res Pract, 2013, 2013: 349512. DOI: 10.1155/2013/349512 [11] KLINGELE M, STADLER T, FLISER D, et al. Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction[J]. Crit Care, 2017, 21(1): 294. DOI: 10.1186/s13054-017-1870-3 [12] BURRY LD, TUNG DD, HALLETT D, et al. Regional citrate anticoagulation for PrismaFlex continuous renal replacement therapy[J]. Ann Pharmacother, 2009, 43(9): 1419-1425. DOI: 10.1345/aph.1M182 [13] SPONHOLZ C, BAYER O, KABISCH B, et al. Anticoagulation strategies in venovenous hemodialysis in critically ill patients: A five-year evaluation in a surgical intensive care unit[J]. Sci World J, 2014, 2014: 808320. http://pubmedcentralcanada.ca/pmcc/articles/PMC4274656/ [14] KALB R, KRAM R, MORGERA S, et al. Regional citrate anticoagulation for high volume continuous venovenous hemodialysis in surgical patients with high bleeding risk[J]. Ther Apher Dial, 2013, 17(2): 202-212. DOI: 10.1111/j.1744-9987.2012.01101.x [15] ZHENG Y, XU Z, ZHU Q, et al. Citrate pharmacokinetics in critically ill patients with acute kidney injury[J]. PLoS One, 2013, 8(6): e65992. DOI: 10.1371/journal.pone.0065992 [16] RODRIGUEZ K, SRIVATHS PR, TAL L, et al. Regional citrate anticoagulation for continuous renal replacement therapy in pediatric patients with liver failure[J]. PLoS One, 2017, 12(8): e0182134. DOI: 10.1371/journal.pone.0182134 [17] NING QQ, GAO Y, DUAN ML, et al. Efficacy and safety of regional citrate anticoagulation in patients with severe liver diseases and acute kidney injury[J]. J Clin Hepatol, 2020, 36(5): 1055-1058. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.05.021宁琪琪, 高原, 段美丽, 等. 局部枸橼酸抗凝在接受连续性肾脏替代治疗的肝病合并急性肾损伤中的应用效果观察[J]. 临床肝胆病杂志, 2020, 36(5): 1055-1058. DOI: 10.3969/j.issn.1001-5256.2020.05.021 [18] SCHULTHEIβ C, SAUGEL B, PHILLIP V, et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: A prospective observational study[J]. Crit Care, 2012, 16(4): r162. DOI: 10.1186/cc11485 [19] LAHMER T, MESSER M, RASCH S, et al. Sustained low-efficiency dialysis with regional citrate anticoagulation in medical intensive care unit patients with liver failure: A prospective study[J]. J Crit Care, 2015, 30(5): 1096-1100. DOI: 10.1016/j.jcrc.2015.06.006 [20] WEINBERG JM, VENKATACHALAM MA, ROESER NF, et al. Mitochondrial dysfunction during hypoxia/reoxygenation and its correction by anaerobic metabolism of citric acid cycle intermediates[J]. Proc Natl Acad Sci U S A, 2000, 97(6): 2826-2831. DOI: 10.1073/pnas.97.6.2826 [21] FELDKAMP T, WEINBERG JM, HÖRBELT M, et al. Evidence for involvement of nonesterified fatty acid-induced protonophoric uncoupling during mitochondrial dysfunction caused by hypoxia and reoxygenation[J]. Nephrol Dial Transplant, 2009, 24(1): 43-51. http://www.ncbi.nlm.nih.gov/pubmed/18678559 [22] YAO YH, GAN JH, ZHAO WF. Effect of plasma exchange combined with continuous renal replacement therapy on the prognosis of patients with HBV-related acute-on-chronic liver failure and acute kidney injury[J]. J Clin Hepatol, 2019, 35(5): 1065-1069. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.05.026姚运海, 甘建和, 赵卫峰. 血浆置换联合持续性肾脏替代治疗对HBV相关慢加急性肝衰竭合并急性肾损伤患者预后的影响[J]. 临床肝胆病杂志, 2019, 35(5): 1065-1069. DOI: 10.3969/j.issn.1001-5256.2019.05.026 [23] BROMAN M, KLARIN B, SANDIN K, et al. Simplified citrate anticoagulation for CRRT without calcium replacement[J]. ASAIO J, 2015, 61(4): 437-442. DOI: 10.1097/MAT.0000000000000226 [24] TOLWANI A, WILLE KM. Advances in continuous renal replacement therapy: Citrate anticoagulation update[J]. Blood Purif, 2012, 34(2): 88-93. DOI: 10.1159/000342378 [25] LINK A, KLINGELE M, SPEER T, et al. Total-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients[J]. Crit Care, 2012, 16(3): r97. DOI: 10.1186/cc11363 [26] WANG J, YU Y, SUN SQ, et al. Application of continuous renal replacement therapy with regional citrate anticoagulation in patients at high risk of bleeding[J]. Chin J Blood Purificat, 2015, 14(7): 404-407. (in Chinese) DOI: 10.3969/j.issn.1671-4091.2015.07.006王佳, 余毅, 孙淑清, 等. 局部枸橼酸体外抗凝在高危出血风险患者持续肾脏替代治疗中的应用[J]. 中国血液净化, 2015, 14(7): 404-407. DOI: 10.3969/j.issn.1671-4091.2015.07.006 [27] KHADZHYNOV D, SCHELTER C, LIEKER I, et al. Incidence and outcome of metabolic disarrangements consistent with citrate accumulation in critically ill patients undergoing continuous venovenous hemodialysis with regional citrate anticoagulation[J]. J Crit Care, 2014, 29(2): 265-271. DOI: 10.1016/j.jcrc.2013.10.015 [28] HILL S, CREIGHTON E, WALTER E. The safety of regional citrate anticoagulation in renal replacement therapy[J]. J Intensive Care Soc, 2018, 19(1): 86. DOI: 10.1177/1751143717735749 [29] HONORE PM, de BELS D, REDANT S, et al. Inducible metabolic pathway for citrate metabolism in case of major liver dysfunction: Fact or fiction?[J]. Crit Care, 2019, 23(1): 166. DOI: 10.1186/s13054-019-2432-7 [30] HONORE PM, MUGISHA A, DAVID C, et al. In severe liver disease, citrate can be used safely: The question remains-by which mechanism[J]. Crit Care, 2020, 24(1): 63. DOI: 10.1186/s13054-020-2801-2 [31] DEVAUCHELLE P, PAGE M, BRUN P, et al. Continuous haemodialysis with citrate anticoagulation in patients with liver failure: Three cases[J]. Ann Fr Anesth Reanim, 2012, 31(6): 543-546. DOI: 10.1016/j.annfar.2012.01.036 [32] SLOWINSKI T, MORGERA S, JOANNIDIS M, et al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: The Liver Citrate Anticoagulation Threshold (L-CAT) observational study[J]. Crit Care, 2015, 19: 349. DOI: 10.1186/s13054-015-1066-7 [33] YU Y, PENG S, CEN Z, et al. Applying regional citrate anticoagulation in continuous renal replacement therapy for acute kidney injury patients with acute liver dysfunction: A retrospective observational study[J]. Kidney Blood Press Res, 2018, 43(4): 1065-1074. DOI: 10.1159/000491057 [34] BALOGUN RA, TURGUT F, CALDWELL S, et al. Regional citrate anticoagulation in critically ill patients with liver and kidney failure[J]. J Nephrol, 2012, 25(1): 113-119. DOI: 10.5301/JN.2011.8363 -
本文二维码
计量
- 文章访问数: 471
- HTML全文浏览量: 127
- PDF下载量: 36
- 被引次数: 0
下载:
